Amgen stock holds firm after Q2 sales raised the bar

Amgen Inc. (US0311621009) is trading near its 52-week high after second-quarter revenue reached $10.05 billion and adjusted EPS came in at $6.29. The latest move followed the company's August 4, 2026 earnings release, which also lifted full-year guidance.

Quarterly numbers

Second-quarter revenue rose 9.5% from $9.17 billion a year earlier, while adjusted EPS increased to $6.29 from $6.02. The company now expects 2026 revenue of $38.2 billion to $39.4 billion and adjusted EPS of $22.30 to $23.50.

That guidance compares with prior revenue expectations of $37.0 billion to $38.4 billion and shows management leaning on growth from products such as Repatha, Evenity and Uplizna. Revenue for the first half of 2026 totaled $18.67 billion, which helps explain why the stock has been able to hold close to its recent high.

Price and valuation

At August 17, 2026, 2:15 p.m. IST, Amgen traded at $415.21, with a market cap of $224.6 billion, a day range of $410.50 to $415.38, and a 52-week range of $269.77 to $421.79. The shares are less than 1.6 percent below the high and more than 53 percent above the low, which keeps valuation debate alive after the post-earnings rally.

Analyst tone has also improved. MarketBeat's latest coverage says the consensus rating is Hold with an average target price of $372.39, while several firms lifted targets after the earnings beat.

Hyderabad expansion

Amgen also added a new operating detail on August 12, 2026, when it said it will open a Science and Innovation Center in Hyderabad in 2027. The site will expand the company's research network and support discovery chemistry, drug metabolism and precision medicine work.

For investors, that adds a second story line beyond the quarter: near-term execution is showing up in the numbers, while the research build-out points to longer-dated pipeline support.

MariTide remains the watch item

The company's product story still centers on its broader biology platform and on MariTide, the obesity candidate now moving through development. That matters because Amgen's 26 percent growth in six key growth drivers in the second quarter showed how quickly the portfolio can offset pressure in older franchises.

Amgen's commercial mix still includes Repatha, Evenity, Uplizna, Tezspire and Imdelltra, so the stock is being priced on more than one product cycle. The current debate is whether the 2026 guidance raise is the start of a longer re-rating or just a strong quarter.

Amgen shares near the high

Amgen stock closed at $415.21 on the latest session cited in the market data, above its 50-day average of $370.57 and 200-day average of $358.99. The share price is also just under the $421.79 52-week high, leaving little room between the current quote and the top of the range.

More on Amgen

Amgen develops human therapeutics across oncology, bone health, inflammation and cardiovascular disease, with products including Repatha, Prolia, Evenity and Tezspire. The company's portfolio mix is the main reason its second-quarter results drew so much attention from traders and analysts.

Amgen stock quote

Amgen stock was priced at $415.21 as of August 17, 2026, with a market cap of $224.6 billion and a 52-week range of $269.77 to $421.79.

Fact box

Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 17, 2026, 2:15 p.m. ET): $415.21 USD
Market cap: $224.6 billion (as of August 17, 2026)
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100